Cover Image

Novel drug delivery systems in the management of CNS disorders /

Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer'...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Chawla, Pooja A. (Editor), Loebenberg, Raimar (Editor), Dua, Kamal (Editor), Parikh, Vinay (Editor), Chawla, Viney (Editor)
Format: eBook
Language:English
Published: London : Academic Press, [2025]
Subjects:
Drug delivery systems.
Central nervous system > Diseases > Chemotherapy.
Drug Delivery Systems
Systèmes d'administration de médicaments.
Système nerveux central > Maladies > Chimiothérapie.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Novel Drug Delivery Systems in the Management of CNS Disorders
  • Novel Drug Delivery Systems in the management of CNS Disorders
  • Copyright
  • Dedication
  • Contents
  • Contributors
  • About editors
  • Foreword
  • Preface
  • Introduction
  • I
  • Introduction to drug delivery to the CNS
  • 1
  • General anatomy and physiology of the brain
  • 1. Introduction
  • 2. Anatomy
  • 2.1 Meninges
  • 2.2 Ventricular system of the brain
  • 2.3 Cerebrospinal fluid
  • 2.4 Forebrain
  • 2.4.1 Telencephalon
  • 2.4.1.1 Cerebrum
  • 2.4.1.2 Basal ganglia
  • 2.4.1.3 Hippocampus
  • 2.4.1.4 Amygdala
  • 2.4.2 Diencephalon
  • 2.4.2.1 Thalamus
  • 2.4.2.2 Hypothalamus
  • 2.5 Midbrain (diencephalon)
  • 2.6 Hindbrain (rhombencephalon)
  • 2.6.1 Pons
  • 2.6.2 Medulla oblongata
  • 2.6.3 Cerebellum
  • 3. Physiology
  • 3.1 Neurohumoral transmission
  • 3.1.1 Glutamate
  • 3.1.2 GABA
  • 3.1.3 Glycine
  • 3.1.4 Serotonin
  • 3.1.5 Dopamine
  • 4. Conclusion
  • Acknowledgments
  • References
  • 2
  • Drug delivery to brain: Formulation challenges and potential approaches
  • 1. Introduction
  • 2. Brain barriers
  • 2.1 The endothelial blood brain barrier
  • 2.2 Glia limitans
  • 2.3 Choroid plexus and blood cerebrospinal fluid barrier (BCSFB)
  • 2.4 Additional brain barriers
  • 3. Nanotechnology-based drug delivery systems
  • 3.1 Nanoparticles
  • 3.2 Liposomes
  • 3.3 Solid lipid nanoparticles (SLNs)
  • 3.4 Nanostructured lipid carriers (NLCs)
  • 4. Approaches to overcome brain barriers
  • 4.1 Convection-enhanced delivery (CED)
  • 4.2 Focused ultrasound (FUS)-mediated BBB disruption
  • 4.3 Implantable devices
  • 4.4 Active targeting
  • 4.5 Intranasal delivery
  • 5. Challenges for scale-up of nano-formulations
  • 6. Conclusion and future prospects
  • References
  • 3
  • Possible targets in the management of various CNS disorders
  • 1. Introduction.
  • 2.4.5.3 GDEPT/VDEPT
  • gene-directed enzyme prodrug therapy/vírus-directed enzyme prodrug therapy
  • 2.5 Prodrug advances in different diseases
  • 2.5.1 Parkinson disease (PD)
  • 2.5.2 Alzheimer's disease
  • 2.5.3 Brain tumor
  • 3. Conclusion
  • References
  • 6
  • Traditional practices in CNS drug delivery
  • 1. Introduction
  • 2. Alzheimer's disease
  • 3. Parkinson's disease
  • 4. Epilepsy
  • 5. Types of epilepsy
  • 6. Structural components of BBB
  • 7. Emphasize on drugs: Improved drug delivery to the brain
  • 7.1 Nanocarriers in CNS drug delivery
  • 8. Liposomes
  • 9. Micelles
  • 10. Solid lipid nanoparticles
  • 11. Microspheres
  • 12. Nasal-to-brain drug administration
  • 13. Nanocarriers' neurotoxic properties
  • 14. Models for CNS delivery of drug in vivo and in vitro
  • 15. In vitro models for CNS delivery of drug
  • 16. Primary mono-cell culture
  • 17. Co-culture
  • 18. Triple cultures
  • 19. In vivo models for CNS drug delivery
  • 20. Rodent model
  • 21. Zebrafish model
  • 22. Drosophila model
  • 23. Concluding remarks and future exploration
  • References
  • 7
  • Emerging need of novel drug delivery systems in management of CNS disorders
  • 1. Introduction
  • 1.1 Current challenges in treating CNS disorders
  • 1.2 Novel drug delivery systems: A hope for breaching the barriers
  • 2. CNS targeting: Approaches using novel formulations
  • 2.1 Vesicular drug delivery systems
  • 2.2 Polymeric drug delivery system
  • 2.3 Lipoidal drug delivery system
  • 2.4 Carbon-based drug delivery system
  • 3. Nanocarriers for targeting CNS disorders
  • 3.1 Alzheimer's disease
  • 3.2 Parkinson's disease
  • 3.3 Hungtington's disease (HD)
  • 3.4 Schizophrenia
  • 4. Challenges
  • 5. Conclusion
  • References
  • 8
  • Nose to brain drug delivery through advanced drug delivery systems
  • 1. Introduction.
  • 1.1 Advantages, challenges, and barriers in nose-to-brain drug delivery
  • 1.2 Advantages
  • 1.3 Challenges
  • 1.3.1 Trigeminal pathway
  • 1.3.2 Olfactory pathway
  • 1.4 Pharmacokinetics of drugs delivered to brain through nasal route
  • 2. Potential applications in neurological disorders
  • 3. Advanced drug delivery systems for nose-to-brain drug delivery
  • 3.1 Nanocarriers
  • 3.1.1 Nanoparticles for nose-to-brain drug delivery
  • 3.1.2 Nanocarriers for nose-to-brain drug delivery
  • 3.2 Mucoadhesion
  • 4. Challenges and key considerations for successful translation to clinical practice
  • 5. Conclusion
  • References
  • 9
  • Physiologically based pharmacokinetic (PBPK) modeling for CNS delivery
  • 1. Introduction
  • 2. Modeling of transporter mediated drug absorption, interactions and clearance based on physiological principles
  • 3. PBPK model for drug transit to the brain via transferrin receptors
  • 4. Drug disposition in the brain: In vitro to in vivo extrapolation linked to physiologically based pharmacokinetic models
  • 5. CNS delivery in an anti-Alzheimer medication using a novel anionic polymer as a carrier
  • 6. PBPK modeling approach for human CNS drug distribution predictions
  • 7. Investigating the CNS transit characteristics using mathematical modeling and simulation
  • 8. PBPK model for plasma protein bound drug delivery at brain
  • 9. Modifying the pharmacokinetics of medicines that target the central nervous system with lipid nanoparticles
  • 10. Nanocarriers for effective CNS delivery
  • 11. Magnetic iron oxide nanoparticles for drug releaseand brain imaging
  • 12. Mouse brain antibody disposition PBPK model
  • 13. In vitro BBB experimental models for CNS drug delivery
  • 14. Applications of exosomes as CNS drug delivery devices
  • 15. Enhanced CNS drug delivery through nanotechnology for schizophrenia management.
  • 16. Transient opening of the BBB by vasoactive peptides to improve CNS drug delivery
  • 17. Treatment of brain tumors using drug delivery to the CNS
  • 18. Nanoemulsions in CNS drug delivery
  • 19. Pharmacokinetics of CNS penetration
  • 20. Current strategies for targeted brain drug delivery
  • 21. Pharmacokinetic model (physiologically-based) of the brain regional lipid variance
  • 22. A translational platform PBPK model for antibody disposition in the brain
  • 23. Blood-brain barrier transit and central nervous system effects of drugs
  • 24. Development of a frontal cortex pharmacokinetics and zone-specific PBPK brain model to assess hippocampus
  • 25. Physiologically based pharmacokinetic modeling of nanoparticle bio-dissemination
  • 26. Essential brain PBPK model for antibody therapeutics for CNS syndrome
  • 27. Assuming drug concentration-time profiles in several CNS compartments
  • 28. Physiologically based pharmacokinetic (PBPK) model for bio-dissemination of radiolabeled peptides in patients along neuroen ...
  • 29. PBPK modelling of nanomaterials
  • 30. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics
  • 31. PBPK modeling for presuming brain levels of drugs in rat
  • 32. PBPK model exploring the blood-milk barrier in lactating breeds to dairy goats and cows
  • 33. PBPK model for kids about to reach maturation
  • 34. The aspect of the physiologically based pharmacokinetic model (PBPK) in pharmaceuticals and environmental chemical risk ass ...
  • 35. PBPK modeling on assuming human CNS pharmacokinetics
  • References
  • II
  • Novel drug delivery systems to specific CNS disorders
  • 10
  • Superparamagnetic iron oxide nanoparticles and their potential role in the diagnosis and therapeutics of vario ...
  • 1. Introduction
  • 2. Synthesis and characterization of SPIONs
  • 2.1 Routes of synthesis of SPIONs.